The suitability of matrix assisted laser desorption/ionization time of flight mass spectrometry in a laboratory developed test using cystic fibrosis carrier screening as a model

Daniel H. Farkas, Nicholas E. Miltgen, Jay Stoerker, Dirk Van Den Boom, W Edward Jr. Highsmith, Lesley Cagasan, Ron McCullough, Reinhold Mueller, Lin Tang, John Tynan, Courtney Tate, Allan Bombard

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We designed a laboratory developed test (LDT) by using an open platform for mutation/polymorphism detection. Using a 108-member (mutation plus variant) cystic fibrosis carrier screening panel as a model, we completed the last phase of LDT validation by using matrix-assisted laser desorption/ionization time of flight mass spectrometry. Panel customization was accomplished via specific amplification primer and extension probe design. Amplified genomic DNA was subjected to allele specific, single base extension endpoint analysis by mass spectrometry for inspection of the cystic fibrosis transmembrane regulator gene (NM-000492.3). The panel of mutations and variants was tested against 386 blinded samples supplied by "authority" laboratories highly experienced in cystic fibrosis transmembrane regulator genotyping; >98% concordance was observed. All discrepant and discordant results were resolved satisfactorily. Taken together, these results describe the concluding portion of the LDT validation process and the use of mass spectrometry to detect a large number of complex reactions within a single run as well as its suitability as a platform appropriate for interrogation of scores to hundreds of targets.

Original languageEnglish (US)
Pages (from-to)611-619
Number of pages9
JournalJournal of Molecular Diagnostics
Volume12
Issue number5
DOIs
StatePublished - Sep 2010

Fingerprint

Cystic Fibrosis
Mass Spectrometry
Lasers
Mutation
Regulator Genes
Alleles
DNA

ASJC Scopus subject areas

  • Molecular Medicine
  • Pathology and Forensic Medicine

Cite this

The suitability of matrix assisted laser desorption/ionization time of flight mass spectrometry in a laboratory developed test using cystic fibrosis carrier screening as a model. / Farkas, Daniel H.; Miltgen, Nicholas E.; Stoerker, Jay; Van Den Boom, Dirk; Highsmith, W Edward Jr.; Cagasan, Lesley; McCullough, Ron; Mueller, Reinhold; Tang, Lin; Tynan, John; Tate, Courtney; Bombard, Allan.

In: Journal of Molecular Diagnostics, Vol. 12, No. 5, 09.2010, p. 611-619.

Research output: Contribution to journalArticle

Farkas, DH, Miltgen, NE, Stoerker, J, Van Den Boom, D, Highsmith, WEJ, Cagasan, L, McCullough, R, Mueller, R, Tang, L, Tynan, J, Tate, C & Bombard, A 2010, 'The suitability of matrix assisted laser desorption/ionization time of flight mass spectrometry in a laboratory developed test using cystic fibrosis carrier screening as a model', Journal of Molecular Diagnostics, vol. 12, no. 5, pp. 611-619. https://doi.org/10.2353/jmoldx.2010.090233
Farkas, Daniel H. ; Miltgen, Nicholas E. ; Stoerker, Jay ; Van Den Boom, Dirk ; Highsmith, W Edward Jr. ; Cagasan, Lesley ; McCullough, Ron ; Mueller, Reinhold ; Tang, Lin ; Tynan, John ; Tate, Courtney ; Bombard, Allan. / The suitability of matrix assisted laser desorption/ionization time of flight mass spectrometry in a laboratory developed test using cystic fibrosis carrier screening as a model. In: Journal of Molecular Diagnostics. 2010 ; Vol. 12, No. 5. pp. 611-619.
@article{21e0a206ba90495eb5b07b81c12bd59a,
title = "The suitability of matrix assisted laser desorption/ionization time of flight mass spectrometry in a laboratory developed test using cystic fibrosis carrier screening as a model",
abstract = "We designed a laboratory developed test (LDT) by using an open platform for mutation/polymorphism detection. Using a 108-member (mutation plus variant) cystic fibrosis carrier screening panel as a model, we completed the last phase of LDT validation by using matrix-assisted laser desorption/ionization time of flight mass spectrometry. Panel customization was accomplished via specific amplification primer and extension probe design. Amplified genomic DNA was subjected to allele specific, single base extension endpoint analysis by mass spectrometry for inspection of the cystic fibrosis transmembrane regulator gene (NM-000492.3). The panel of mutations and variants was tested against 386 blinded samples supplied by {"}authority{"} laboratories highly experienced in cystic fibrosis transmembrane regulator genotyping; >98{\%} concordance was observed. All discrepant and discordant results were resolved satisfactorily. Taken together, these results describe the concluding portion of the LDT validation process and the use of mass spectrometry to detect a large number of complex reactions within a single run as well as its suitability as a platform appropriate for interrogation of scores to hundreds of targets.",
author = "Farkas, {Daniel H.} and Miltgen, {Nicholas E.} and Jay Stoerker and {Van Den Boom}, Dirk and Highsmith, {W Edward Jr.} and Lesley Cagasan and Ron McCullough and Reinhold Mueller and Lin Tang and John Tynan and Courtney Tate and Allan Bombard",
year = "2010",
month = "9",
doi = "10.2353/jmoldx.2010.090233",
language = "English (US)",
volume = "12",
pages = "611--619",
journal = "Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Association of Molecular Pathology",
number = "5",

}

TY - JOUR

T1 - The suitability of matrix assisted laser desorption/ionization time of flight mass spectrometry in a laboratory developed test using cystic fibrosis carrier screening as a model

AU - Farkas, Daniel H.

AU - Miltgen, Nicholas E.

AU - Stoerker, Jay

AU - Van Den Boom, Dirk

AU - Highsmith, W Edward Jr.

AU - Cagasan, Lesley

AU - McCullough, Ron

AU - Mueller, Reinhold

AU - Tang, Lin

AU - Tynan, John

AU - Tate, Courtney

AU - Bombard, Allan

PY - 2010/9

Y1 - 2010/9

N2 - We designed a laboratory developed test (LDT) by using an open platform for mutation/polymorphism detection. Using a 108-member (mutation plus variant) cystic fibrosis carrier screening panel as a model, we completed the last phase of LDT validation by using matrix-assisted laser desorption/ionization time of flight mass spectrometry. Panel customization was accomplished via specific amplification primer and extension probe design. Amplified genomic DNA was subjected to allele specific, single base extension endpoint analysis by mass spectrometry for inspection of the cystic fibrosis transmembrane regulator gene (NM-000492.3). The panel of mutations and variants was tested against 386 blinded samples supplied by "authority" laboratories highly experienced in cystic fibrosis transmembrane regulator genotyping; >98% concordance was observed. All discrepant and discordant results were resolved satisfactorily. Taken together, these results describe the concluding portion of the LDT validation process and the use of mass spectrometry to detect a large number of complex reactions within a single run as well as its suitability as a platform appropriate for interrogation of scores to hundreds of targets.

AB - We designed a laboratory developed test (LDT) by using an open platform for mutation/polymorphism detection. Using a 108-member (mutation plus variant) cystic fibrosis carrier screening panel as a model, we completed the last phase of LDT validation by using matrix-assisted laser desorption/ionization time of flight mass spectrometry. Panel customization was accomplished via specific amplification primer and extension probe design. Amplified genomic DNA was subjected to allele specific, single base extension endpoint analysis by mass spectrometry for inspection of the cystic fibrosis transmembrane regulator gene (NM-000492.3). The panel of mutations and variants was tested against 386 blinded samples supplied by "authority" laboratories highly experienced in cystic fibrosis transmembrane regulator genotyping; >98% concordance was observed. All discrepant and discordant results were resolved satisfactorily. Taken together, these results describe the concluding portion of the LDT validation process and the use of mass spectrometry to detect a large number of complex reactions within a single run as well as its suitability as a platform appropriate for interrogation of scores to hundreds of targets.

UR - http://www.scopus.com/inward/record.url?scp=77956819100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956819100&partnerID=8YFLogxK

U2 - 10.2353/jmoldx.2010.090233

DO - 10.2353/jmoldx.2010.090233

M3 - Article

VL - 12

SP - 611

EP - 619

JO - Journal of Molecular Diagnostics

JF - Journal of Molecular Diagnostics

SN - 1525-1578

IS - 5

ER -